Study Summary
A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 5 years.
Want to learn more about this trial?
Request More InfoInterventions
RTx-015GENETIC
Intravitreal injection using gene therapy to deliver an optogenetic gene to the eye. Cells in the retina use this Optogenetic gene to make a protein that responds to light.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Retina Vitreous Associates Medical Group | Beverly Hills | California | United States |
| UCI Alpha Clinic | Orange | California | United States |
| UPMC Vision Institute | Pittsburgh | Pennsylvania | United States |
| Retina Consultants of Texas Research Centers | Bellaire | Texas | United States |